TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04023617

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Nivolumab 300mg + docetaxel 75mg/m2 IV q3w Nivolumab 200mg IV q2w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 300mg + docetaxel 75mg/m2 IV q3w Nivolumab 200mg IV q2w
Study: NCT00430937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Description: 4 mg/kg intravenous once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: 1 g intravenous twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teicoplanin
Description: 400 mg intravenous once daily following a loading dose of 400 mg administered at 0, 12, 24 hours on day one.
Study: NCT01777945

Intervention type: DRUG
Intervention: capecitabine
Description: Participants received capecitabine according to individualized physician-prescribed regimen.

Intervention type: DRUG
Intervention: docetaxel
Description: Participants received docetaxel according to individualized physician-prescribed regimens.
Study: NCT03623061

Intervention type: DIAGNOSTIC_TEST
Intervention: F-Point
Description: F-Point (point of care in vitro diagnostic device for measuring plasma fibrinogen concentration)

Intervention type: DIAGNOSTIC_TEST
Intervention: F-Point
Description: F-Point (point of care in vitro diagnostic device for measuring plasma fibrinogen concentration)

Intervention type: DIAGNOSTIC_TEST
Intervention: F-Point
Description: F-Point (point of care in vitro diagnostic device for measuring plasma fibrinogen concentration)
Study: NCT01072825

Intervention type: OTHER
Intervention: questionnaires
Description: a descriptive questionnaire, SF-36, , bone questionnaires, Baecke physical activity questionnaire, voice evaluation

Intervention type: BIOLOGICAL
Intervention: blood sampling
Description: LFT (AST, ALT), CRP, creatinine, glucose, Total Cholesterol, Triglycerides, HDL-CH, LDL-CH, 25OH vitamin D, PSA if\> 45 years, Hematocrit, testosterone, sex hormone-binding globulin, free testosterone , oestradiol, prolactin, luteinizing hormone, TSH, androgeengevoeligheids test (CAG RL), oral glucose tolerance test

Intervention type: OTHER
Intervention: clinical evaluation
Description: height, weight, blood pressure, chestcircumference, waist circumference, grip strength, measuring 2 ° and 4 ° finger, and Ferriman Gallwey score

Intervention type: OTHER
Intervention: Dermatology evaluation
Description: Evaluation of the hair pattern, using the Leeds acne classification scale, acne scars through ECCA scale (échelle d'évaluation clinique des cicatrices d'acné), androgenetic alopecia, and sebummetrie

Intervention type: OTHER
Intervention: Bone evaluation
Description: PQCT scanner, BMD assessment
Study: NCT01659255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: Capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: Capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: Capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: Capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: Capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: Capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: Capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: Capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: Capsules administered orally
Study: NCT03929861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole (BAYT006267) 150 mg capsules
Description: Fluconazole 150 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole (BAYT006267) 150 mg capsules
Description: Fluconazole 150 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole 150 mg capsules (DiflucanTM)
Description: Fluconazole 150 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole 150 mg capsules (DiflucanTM)
Description: Fluconazole 150 mg
Study: NCT00790881

Intervention type: DRUG
Group type: OTHER
Intervention: Artemether/Lumefantrine
Description: Coartem (fixed dose Artemether20mg /Lumefantrine 120mg) Dose: 4 tablets(80mg/480mg) twice daily for 3 days at 0,8,24,36,48 and 60 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether/ lumefantrine
Description: Coartem (fixed dose Artemether20mg /Lumefantrine 120mg) Dose: 4 tablets(80mg/480mg) twice daily for 3 days at 0,8,24,36,48 and 60 hours
Study: NCT03724409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [90]Y-DOTATOC
Description: Intra-arterial infusion to the liver of \[90\]Y-DOTATOC. The administered dose is determined by cohort and is dependent upon the results of the previous cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [90]Y-DOTATOC
Description: Intra-arterial infusion to the liver of \[90\]Y-DOTATOC. The administered dose is determined by cohort and is dependent upon the results of the previous cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [90]Y-DOTATOC
Description: Intra-arterial infusion to the liver of \[90\]Y-DOTATOC. The administered dose is determined by cohort and is dependent upon the results of the previous cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [90]Y-DOTATOC
Description: Intra-arterial infusion to the liver of \[90\]Y-DOTATOC. The administered dose is determined by cohort and is dependent upon the results of the previous cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [90]Y-DOTATOC
Description: Intra-arterial infusion to the liver of \[90\]Y-DOTATOC. The administered dose is determined by cohort and is dependent upon the results of the previous cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [90]Y-DOTATOC
Description: Intra-arterial infusion to the liver of \[90\]Y-DOTATOC. The administered dose is determined by cohort and is dependent upon the results of the previous cohort.
Study: NCT02155647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab was administered at a dose of 10 milligram per kilogram (mg/kg) as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab was administered at a dose of 10 milligram per kilogram (mg/kg) as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs.
Study: NCT02530450

Intervention type: DEVICE
Intervention: continuous glucose monitoring (CGM)
Description: All subjects in Groups 1 and 2 wore the CGM device at time points 0, 3 months, and 6 months. Group 1 did not review CGM data at time 0, but did review CGM data at time point 3 months and 6 months. Group 2 reviewed CGM data at all time points.

Intervention type: DEVICE
Intervention: continuous glucose monitoring (CGM)
Description: All subjects in Groups 1 and 2 wore the CGM device at time points 0, 3 months, and 6 months. Group 1 did not review CGM data at time 0, but did review CGM data at time point 3 months and 6 months. Group 2 reviewed CGM data at all time points.
Study: NCT02400281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Study: NCT00374296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGCD0103
Description: MGCD0103 administered orally three-times per week
Study: NCT05492565

Intervention type: DRUG
Intervention: Tenofovir Disoproxil Fumarate 300 MG Oral Tablet
Description: Pre-exposure prophylaxis with coformulated Tenofovir Disoproxil Fumarate 300mg/Emtricitabine 200mg oral QD to prevent HIV infection

Intervention type: DRUG
Intervention: Tenofovir Disoproxil Fumarate 300 MG Oral Tablet
Description: Pre-exposure prophylaxis with coformulated Tenofovir Disoproxil Fumarate 300mg/Emtricitabine 200mg oral QD to prevent HIV infection

Intervention type: DRUG
Intervention: Tenofovir Disoproxil Fumarate 300 MG Oral Tablet
Description: Pre-exposure prophylaxis with coformulated Tenofovir Disoproxil Fumarate 300mg/Emtricitabine 200mg oral QD to prevent HIV infection

Intervention type: DRUG
Intervention: Tenofovir Disoproxil Fumarate 300 MG Oral Tablet
Description: Pre-exposure prophylaxis with coformulated Tenofovir Disoproxil Fumarate 300mg/Emtricitabine 200mg oral QD to prevent HIV infection
Study: NCT01277952

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: Brain pace maker, implanted in the brain
Study: NCT01085799

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education Intervention
Description: This is a health hygiene education strategy which encourages the pro-active role of both teachers and students and changes in attitudes and practices with the aim of keeping the level of parasite infection low, through increased knowledge.
Study: NCT02158390

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Jasper-EMT with words and AAC
Description: Jasper-EMT with words and AAC~A therapist plus parent implemented social communication intervention which include use of the iPad for a mode of communication. A total of 6 hour long workshops with the parent and 42 hour long intervention sessions with the child occur; half include the parent as therapist and occur in the home. The treatment lasts approximately 4 months.
Study: NCT01760512

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric bypass
Description: Gastric bypass

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric bypass
Description: Gastric bypass
Study: NCT01522365

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Abutment-supported XiVE CAD/CAM bridge
Description: One side will be provided with a XiVE CAD/CAM bridge placed directly on an abutment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implant-supported XiVE CAD/CAM bridge
Description: One side will be provided with a XiVE CAD/CAM bridge fixed directly on the implant
Study: NCT01824407

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrohydraulic-generated shock wave

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham device plus standard of care
Study: NCT02400281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacytidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Study: NCT02519777

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for maraviroc (MVC)
Description: Administered orally as one 150 mg tablet BID OR two 300 mg tablet BID OR one 300 mg tablet BID depending upon background ARV regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for maraviroc (MVC)
Description: Administered orally as one 150 mg tablet BID OR two 300 mg tablet BID OR one 300 mg tablet BID depending upon background ARV regimen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for dolutegravir (DTG)
Description: Administered orally as one 50 mg tablet BID OR one 50 mg tablet QD depending upon background ARV regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG)
Description: Administered orally as one 50 mg tablet BID OR one 50 mg tablet QD depending upon background ARV regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG)
Description: Administered orally as one 50 mg tablet BID OR one 50 mg tablet QD depending upon background ARV regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc (MVC)
Description: Administered orally as one 150 mg tablet BID OR two 300 mg tablet BID OR one 300 mg tablet BID depending upon background ARV regimen
Study: NCT03661658

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Using short dental implant
Description: Using short dental implant for patients with atrophic posterior mandible.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inferior alveolar nerve lateralization with simultaneous implant placement
Description: Inferior alveolar nerve lateralization with simultaneous implant placement in atrophic posterior mandible.
Study: NCT03474172

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Cloak Shape Device for Sham Tuina
Description: The Cloak Shape Device for Sham Tuina is exactly the same as the real one, which is opaque and big enough to cover the whole body and arms of a child who is under 6 years old. Two narrow holes are required on the cover, so that the therapist's hands can touch the child through these holes and a sham Tuina will be manipulated

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cloak Shape Device for Genuine Tuina
Description: The Cloak Shape Device for Genuine Tuina is opaque and big enough to cover the whole body and arms of a child who is under 6 years old. Two narrow holes are required on the cover, so that the therapist's hands can touch the child through these holes and a genuine Tuina will be manipulated.
Study: NCT03421236

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ty21a
Description: intravesical administration of Ty21a
Study: NCT01659255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: Capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: Capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: Capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: Capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: Capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: Capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: Capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: Capsules administered orally
Study: NCT02092766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artesunate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: quinine
Study: NCT01862367

Intervention type: DRUG
Intervention: catridecacog
Description: No treatment given. All patients enrolled in this observational study will receive their medication through usual commercial channels.
Study: NCT00885781

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lipid emulsion for TPN
Description: 1-2 g lipid emulsion /kgBW-day, for consecutive 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lipid emulsion for TPN
Description: 1-2 g lipid emulsion /kgBW-day, for consecutive 5 days
Study: NCT02789891

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: D2 lymphadenectomy including No. 14v
Description: After exclusion of T4b, or distant metastasis case by diagnostic laparoscopy, Laparoscopic distal with D2 lymphadenectomy including No. 14v Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lymphadenectomy excluding No. 14v
Description: After exclusion of T4b, or distant metastasis case by diagnostic laparoscopy, Laparoscopic distal gastrectomy with D2 lymphadenectomy excluding No. 14v Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience
Study: NCT02239614

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDENV-PIV 4 µg + alum adjuvant
Description: 0.5 mL of DENV serotypes 1-4 (4 µg / serotype) in alum adjuvant
Study: NCT01331967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone 15-30mg, once daily for 9 months
Study: NCT03429257

Intervention type: OTHER
Intervention: Exposures of interest: Maternal EED and Aflatoxin Exposure
Description: Maternal EED, measured via lactulose: mannitol (L:M) ratios and serum concentrations of antibodies to the bacterial components flagellin and lipopolysaccharide (LPS); Maternal aflatoxin exposure, measured via serum concentration of AFB1-lysine adduct
Study: NCT04955418

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Epi-No®
Description: evaluation, 10 sessions (twice a week for 5 weeks) of perineal preparation with the Epi-No device and revaluation six months after delivery.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Evaluation
Description: evaluation (anamnesis, childbirth data, perineometry, International Consultation on Incontinence Questionnaire - Short Form, Female Sexual Function Index) six months after vaginal delivery.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation
Description: evaluation (anamnesis, childbirth data, perineometry, International Consultation on Incontinence Questionnaire - Short Form, Female Sexual Function Index) six months after vaginal delivery.
Study: NCT02207257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PER977
Description: Reversal of edoxaban-induced anticoagulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PER977
Description: Reversal of edoxaban-induced anticoagulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PER977
Description: Reversal of edoxaban-induced anticoagulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PER977
Description: Reversal of edoxaban-induced anticoagulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PER977
Description: Reversal of edoxaban-induced anticoagulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Reversal of edoxaban-induced anticoagulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Reversal of edoxaban-induced anticoagulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Reversal of edoxaban-induced anticoagulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Reversal of edoxaban-induced anticoagulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Reversal of edoxaban-induced anticoagulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Study: NCT01344187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: riboflavin solution
Description: 0.12% riboflavin ophthalmic solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo solution
Description: 0.0% riboflavin ophthalmic solution

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: KXL System
Description: 30 mW/cm2
Study: NCT01344187

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KXL System
Description: 30 mW/cm2
Study: NCT02963337

Intervention type: DRUG
Intervention: remifentanil
Description: Remifentanil PCA will be used to deliver intravenous drug boluses from 20 to 40 micrograms per 2 min lockout interval.

Intervention type: DRUG
Intervention: combined spinal-epidural analgesia
Description: Patient controlled epidural analgesia will be used to deliver epidural boluses of 6-10 ml of 0,1% bupivacaine with 2 micrograms of fentanyl per ml per 15 min lockout interval.
Study: NCT00281684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB705498 400 mg
Description: SB705498 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB705498 1000 mg
Description: SB705498 1000 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-Codamol
Description: Co-Codamol
Study: NCT03667365

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: aortic valve replacement
Description: aortic valve replacement surgical or transcatheter aortic valve replacement (will be decided by the heart team before randomization)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: strict clinical surveillance
Description: strict clinical surveillance strategy
Study: NCT02751515

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bain De Soliel - Solid
Description: 0.05gm/ cm2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Untreated skin
Description: One site is patched without treatment as control
Study: NCT02177279

Intervention type: OTHER
Group type: OTHER
Intervention: Visit A high wheat bran

Intervention type: OTHER
Group type: OTHER
Intervention: Visit B normal wheat bran

Intervention type: OTHER
Group type: OTHER
Intervention: Follow up normal (8days) and high (1day) bran consumption
Study: NCT04476979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab 8mg/kg D1 and if no response (No decrease of oxygen requirement) a second fixed dose of 400mg wil be administered at D3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone : 10 mg once daily for the first five days (day 1 to day 5) then 5 mg per day for up to 5 days, 2.5mg per day for up to 4 days (or until oxygen supply independency if sooner)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone : 10 mg once daily for the first five days (day 1 to day 5) then 5 mg per day for up to 5 days, 2.5mg per day for up to 4 days (or until oxygen supply independency if sooner)
Study: NCT04535895

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Simultaneous integrated boost
Description: Adjuvant breast cancer irradiation including simultaneous integrated boost
Study: NCT02467569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay020